15 July 2019 - Washington has seen a flurry of activity and bipartisan interest in passing drug pricing legislation this year, but with the August recess approaching and the 2020 elections ahead, advocates for reform worry time is running short.

Congress has two weeks until the August recess, and lawmakers must handle a number of other pressing issues. And despite early momentum, House Democratic leaders are divided with progressives over their drug pricing bill, while in the upper chamber Republicans are balking at some measures backed by Senate Finance Committee Chairman Chuck Grassley (R-Iowa).

Some are already lowering expectations for what Congress will do.

Read The Hill article